Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMINA phase 3 study of intravitreal DE-109 versus sham in active non-infectious posterior segment uveitis
2019-003638-18Phase 3Terminated
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MS-R001 in non-infectious posterior uveitis (NIPU) (2 arms), sponsored by Santen Pharmaceutical. Started Jun 2021; status: terminated.
02
Drugs
MS-R001
03
Conditions
non-infectious posterior uveitis (NIPU)
Beyond the preview
Go deeper on 2019-003638-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003638-18.